Danaher Corporation (DHR) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.033x

Based on the latest financial reports, Danaher Corporation (DHR) has a cash flow conversion efficiency ratio of 0.033x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($1.66 Billion) by net assets ($51.07 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Danaher Corporation - Cash Flow Conversion Efficiency Trend (1990–2024)

This chart illustrates how Danaher Corporation's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read total liabilities of Danaher Corporation for a breakdown of total debt and financial obligations.

Danaher Corporation Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Danaher Corporation ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
S&P Global Inc
NYSE:SPGI
0.048x
Pinduoduo Inc
F:9PDA
0.117x
SIEMENS ENERGY AG ADR/1
F:ENR0
0.272x
Rio Tinto Group
MX:RION
0.046x
Delta Electronics (Thailand) Public Company Limited
BK:DELTA
0.077x
Banco Bilbao Viscaya Argentaria SA ADR
NYSE:BBVA
0.278x
SAFRAN UNSPONS.ADR 1/4
F:SEJU
N/A
BP p.l.c
MX:BPN
0.103x

Annual Cash Flow Conversion Efficiency for Danaher Corporation (1990–2024)

The table below shows the annual cash flow conversion efficiency of Danaher Corporation from 1990 to 2024. For the full company profile with market capitalisation and key ratios, see DHR market cap.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 $49.55 Billion $6.69 Billion 0.135x +0.78%
2023-12-31 $53.49 Billion $7.16 Billion 0.134x -21.25%
2022-12-31 $50.09 Billion $8.52 Billion 0.170x -8.07%
2021-12-31 $45.18 Billion $8.36 Billion 0.185x +18.54%
2020-12-31 $39.78 Billion $6.21 Billion 0.156x +19.60%
2019-12-31 $30.28 Billion $3.95 Billion 0.130x -8.42%
2018-12-31 $28.23 Billion $4.02 Billion 0.142x +8.03%
2017-12-31 $26.37 Billion $3.48 Billion 0.132x -13.57%
2016-12-31 $23.08 Billion $3.52 Billion 0.153x -4.61%
2015-12-31 $23.76 Billion $3.80 Billion 0.160x -0.18%
2014-12-31 $23.45 Billion $3.76 Billion 0.160x +0.36%
2013-12-31 $22.45 Billion $3.59 Billion 0.160x -10.76%
2012-12-31 $19.08 Billion $3.42 Billion 0.179x +15.64%
2011-12-31 $16.97 Billion $2.63 Billion 0.155x +2.25%
2010-12-31 $13.77 Billion $2.08 Billion 0.151x -2.26%
2009-12-31 $11.63 Billion $1.80 Billion 0.155x -18.30%
2008-12-31 $9.81 Billion $1.86 Billion 0.190x +4.63%
2007-12-31 $9.09 Billion $1.65 Billion 0.181x -22.21%
2006-12-31 $6.64 Billion $1.55 Billion 0.233x -1.73%
2005-12-31 $5.08 Billion $1.20 Billion 0.237x +5.95%
2004-12-31 $4.62 Billion $1.03 Billion 0.224x -5.33%
2003-12-31 $3.65 Billion $861.54 Million 0.236x +0.10%
2002-12-31 $3.01 Billion $710.35 Million 0.236x -13.55%
2001-12-31 $2.23 Billion $608.47 Million 0.273x +3.53%
2000-12-31 $1.94 Billion $512.25 Million 0.264x +7.53%
1999-12-31 $1.71 Billion $419.10 Million 0.245x +0.07%
1998-12-31 $1.35 Billion $331.30 Million 0.245x -19.28%
1997-12-31 $916.90 Million $278.40 Million 0.304x +11.93%
1996-12-31 $800.30 Million $217.10 Million 0.271x -8.70%
1995-12-31 $586.30 Million $174.20 Million 0.297x -2.04%
1994-12-31 $476.10 Million $144.40 Million 0.303x -18.77%
1993-12-31 $363.70 Million $135.80 Million 0.373x +78.45%
1992-12-31 $348.40 Million $72.90 Million 0.209x +59.84%
1991-12-31 $319.30 Million $41.80 Million 0.131x -42.96%
1990-12-31 $305.00 Million $70.00 Million 0.230x --

About Danaher Corporation

NYSE:DHR USA Diagnostics & Research
Market Cap
$123.72 Billion
Market Cap Rank
#189 Global
#101 in USA
Share Price
$175.15
Change (1 day)
-2.12%
52-Week Range
$175.15 - $242.05
All Time High
$290.97
About

Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. It operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides bioprocessing technologies, consumables, services, and solutions that advance, accelerate, and integrate the deve… Read more